Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Up 20.8% in March

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 352,300 shares, an increase of 20.8% from the February 28th total of 291,600 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily volume of 141,900 shares, the short-interest ratio is currently 2.5 days.

Nautilus Biotechnology Trading Up 2.5 %

NASDAQ:NAUT traded up $0.02 during midday trading on Wednesday, hitting $0.85. 178,897 shares of the stock were exchanged, compared to its average volume of 99,551. The business has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $2.02. The company has a market capitalization of $107.35 million, a price-to-earnings ratio of -1.52 and a beta of 1.25. Nautilus Biotechnology has a one year low of $0.81 and a one year high of $3.09.

Wall Street Analyst Weigh In

NAUT has been the topic of several recent research reports. Guggenheim set a $2.50 price objective on shares of Nautilus Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group lowered Nautilus Biotechnology from a "neutral" rating to a "sell" rating and reduced their price target for the stock from $2.25 to $1.75 in a research report on Thursday, December 5th.

Insider Buying and Selling

In related news, CEO Sujal M. Patel acquired 53,300 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the purchase, the chief executive officer now directly owns 10,117,788 shares in the company, valued at $10,016,610.12. This represents a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 40.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of Nautilus Biotechnology by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company's stock worth $1,920,000 after acquiring an additional 7,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Nautilus Biotechnology by 11.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company's stock valued at $1,294,000 after purchasing an additional 78,367 shares during the period. Wexford Capital LP increased its stake in Nautilus Biotechnology by 42.4% in the 4th quarter. Wexford Capital LP now owns 325,239 shares of the company's stock worth $546,000 after purchasing an additional 96,889 shares in the last quarter. Renaissance Technologies LLC increased its stake in Nautilus Biotechnology by 61.7% in the 4th quarter. Renaissance Technologies LLC now owns 250,221 shares of the company's stock worth $420,000 after purchasing an additional 95,521 shares in the last quarter. Finally, Citadel Advisors LLC raised its holdings in Nautilus Biotechnology by 171.4% during the 4th quarter. Citadel Advisors LLC now owns 220,220 shares of the company's stock worth $370,000 after buying an additional 139,081 shares during the period. Institutional investors and hedge funds own 50.71% of the company's stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads